Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084936 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A Phase 3 study of Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT06084936: Recruiting Phase 3 study of Lymphoma, sponsored by Hoffmann-La Roche.
NCT06084936 is a Phase 3 study of Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 182 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06084936, a Phase 3 study of Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Bendamustine
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- City of Hope Cancer Center - Duarte
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica - Santa Monica
Texas
- Renovatio Clinical - El Paso - El Paso
- Renovatio Clinical - The Woodlands
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Georgetown University - Washington D.C.
Florida
- University of Miami - Coral Gables
Indiana
- Indiana University - Indianapolis
Michigan
- University of Michigan Health System - Ann Arbor
Missouri
- St. Luke's Hospital - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2023-10-22 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 3 |
What NCT06084936 shows while recruiting
NCT06084936 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT06084936 names 20 study sites across 17 states, led by California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06084936 about?
NCT06084936 is a clinical study titled "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma". The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
What is the current status of trial NCT06084936?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2023-10-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06084936 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT06084936?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT06084936?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084936 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06084936's enrollment target sits among peer trials
182 51st of 299 higher than 249 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI